Scleroderma--developing measures of response.
The scleroderma research community continued its focus on the development and proper validation of the outcome measures for clinical trials in scleroderma during the special interest group meeting at OMERACT 7. Deliberations focused on progress in the assessment of gastrointestinal disease, renal physiology, vascular damage, and the unique challenges inherent in studying pediatric patients with scleroderma.
Furst
Daniel E
DE
University of California at Los Angeles, CA 90025, USA. defurst@mednet.ucla.edu
Khanna
Dinesh
D
Mattucci-Cerinic
Marco
M
Silman
Alan J
AJ
Merkel
Peter A
PA
Foeldvari
Ivan
I
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005385:Fingers; D005767:Gastrointestinal Diseases / Q000209:etiology; D005919:Glomerular Filtration Rate; D006304:Health Status; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology / Q000503:physiopathology; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D011788:Quality of Life; D012107:Research Design; D012594:Scleroderma, Localized / Q000188:drug therapy* / Q000473:pathology; D012595:Scleroderma, Systemic / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D012883:Skin Ulcer / Q000209:etiology / Q000473:pathology